Skip to content
Research Article Open access CC BY 4.0

Functional Abdominal Pain of Children: Therapy with Bacillus Coagulans GBI-30, 6086 and Insight into Its Probiotic Properties

Vishnu Kumar Tandon, Trayambak Dutta, R. Ezhil Arasan

Asian Journal of Pediatric Research · pp. 19–27 · Published 21 Oct 2021

10.9734/ajpr/2021/v7i230211

Abstract

Background: Probiotics are effective in the treatment of functional gastrointestinal disorders in adults but there is lack of enough clinical evidence in children. Aim: To evaluate effectiveness of Bacillus Coagulans GBI-30, 6086 along with digestive enzymes in the treatment of childhood functional abdominal pain (FAP). Methods: Children with FAP, based on the Rome IV criteria (n = 95, aged 5-16 years), received Bacillus Coagulans GBI-30, 6086 along with digestive enzymes from a commercially available preparation - Tummysoft® for three weeks. Treatment response was assessed by improvement in the Quality of Life in Reflux and Dyspepsia Questionnaire (QOLRAD) score and Global Overall Symptom (GOS) scale. Results: Patients diagnosed with FAP upon receiving a 3-week treatment with Bacillus Coagulans GBI-30, 6086 along with digestive enzymes, registered statistically significant improvement in both QOLRAD (Baseline, 30.27 ± 5.95; 10th Day: 108.39 ± 7.06; 21st day: 173.71 ± 6.71, P=0.00) and GOS scale (Baseline, 3.10 ± 0.37; 10th Day: 2.15 ± 0.73; 21st day: 1.00 ± 0.00, P = 0) signifying the efficacy of the probiotic in FAP. Conclusion: Bacillus Coagulans GBI-30, 6086 along with digestive enzymes from a commercially available preparation - Tummysoft® was found to be effective in the treatment of childhood functional abdominal pain (FAP).

Functional abdominal pain probiotic bacillus coagulans quality of life in reflux and dyspepsia questionnaire (QOLRAD) scores, global overall symptom (GOS) scale

References (17)

  1. 1 The International Scientific Association for Probiotics and Prebiotics consensus statement on the scope and appropriate use of the term probiotic [DOI]
  2. 2 Microorganisms with Claimed Probiotic Properties: An Overview of Recent Literature [DOI]
  3. 3 Epidemiology of Pediatric Functional Abdominal Pain Disorders: A Meta-Analysis [DOI]
  4. 4 Potential Use of Bacillus coagulans in the Food Industry [DOI]
  5. 5 Probiotic characteristics of Bacillus coagulans and associated implications for human health and diseases [DOI]
  6. 6 The Gut Microbiome in Adult and Pediatric Functional Gastrointestinal Disorders [DOI]
  7. 7 Probiotic Bacillus coagulans GBI-30, 6086 Improves Protein Absorption and Utilization [DOI]
  8. 8 The microbiota-gut-brain axis in functional gastrointestinal disorders [DOI]
  9. 9 Digestive Enzyme Supplementation in Gastrointestinal Diseases [DOI]
  10. 10 Predicting Persistence of Functional Abdominal Pain From Childhood Into Young Adulthood [DOI]
  11. 11 Integrate genome-based assessment of safety for probiotic strains: Bacillus coagulans GBI-30, 6086 as a case study [DOI]
  12. 12 Bacillus coagulans MA-13: a promising thermophilic and cellulolytic strain for the production of lactic acid from lignocellulosic hydrolysate [DOI]
  13. 13 Epidemiology of gastrointestinal symptoms in young and middle-aged Swiss adults: prevalences and comorbidities in a longitudinal population cohort over 28 years [DOI]
  14. 14 Functional abdominal pain and irritable bowel syndrome in children and adolescents [DOI]
  15. 15 Spores of Bacillus coagulans GBI-30, 6086 show high germination, survival and enzyme activity in a dynamic, computer-controlled in vitro model of the gastrointestinal tract [DOI]
  16. 16 A Review of Digestive Enzyme and Probiotic Supplementation for Functional Gastrointestinal Disorders
  17. 17 Recurrent Abdominal Pain Among Children Attending Government and Private Schools in Delhi [DOI]

Cited by 1

Efficacy and Safety of Bacillus coagulans LBSC in Drug Induced Constipation Associated With Functional Gastrointestinal Disorder: A Double-Blind, Randomized, Interventional, Parallel, Controlled Trial a Clinical Study on Bacillus coagulans LBSC for Drug Induced Constipation Associated With FGIDs

Ankit Rathi, Ravikiran Pagare · Global Advances in Integrative Medicine and Health · 2024

Related research

Article metrics

Real usage data collected on this platform.

39

Page views

0

PDF downloads

4

Outbound clicks

1

Citations

Views over time

Views by country

Approximate, from request IP at view time — not citizenship or institution. Countries with fewer than 5 views are grouped as "Other".

Traffic sources

Referring site, by host.

Views and downloads exclude known bots/crawlers. Citations combines this platform's own DOI-resolved index with each external source's own reported total — see Cited by above for individually listed citing works. Last refreshed 0 seconds ago.